MétaCan
Menu
Back to cohort
Record W3123587989 · doi:10.1787/346071162287

Pharmaceutical Pricing and Reimbursement Policies in Canada

2006· report· en· W3123587989 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

fundA Canadian funder is recorded on the work.
aboutThe title or abstract carries a Canadian signal from the geographic lexicon.
no affNo Canadian affiliation: this work is invisible to an affiliation-only frame.
No Canadian affiliation. An affiliation-only frame, the usual design, would never have seen this work. It is one of the works that make the case for inverting the frame.

Bibliographic record

VenueOECD health working papers · 2006
Typereport
Languageen
FieldEconomics, Econometrics and Finance
TopicPharmaceutical Economics and Policy
Canadian institutionsnot available
FundersHealth Canada
KeywordsReimbursementBusinessEconomicsHealth careEconomic growth

Abstract

fetched live from OpenAlex

This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada's achievements in meeting a range of objectives relating to the pharmaceutical policy.The federal government regulates prices of patented pharmaceutical products with the objective of protecting consumers against excessive prices.Regulation has very likely been responsible for bringing Canada's prices for patented medicines roughly in line with European comparators.Prices of generic products, which are not regulated, are relatively high although high penetration of the Canadian market has been achieved.All Canadians have coverage for drugs provided in hospitals through a publicly financed scheme that furnishes hospital and physician services free of charge to patients.Drugs dispensed outside the hospital setting are not included among the insured benefits guaranteed by the Canadian Health Act.Consequently, two-thirds of the Canadian population, including most employees and their families, obtains such coverage through private health insurance, while most senior citizens, together with designated groups of vulnerable populations, are covered by provincial, territorial or federal plans.In most cases, patients share in the costs of reimbursed medicines through copayments or co-insurance, sometimes after meeting a deductible.The lack of protection against the risk of catastrophic out-of-pocket spending for drugs remains an issue for a small part of the Canadian population, concentrated in the Atlantic Provinces.Reflecting these coverage and reimbursement arrangements, 54% of drug expenditures are financed by private insurances and households.Drug expenditures have been increasing very rapidly in recent years.Formulary management, now facilitated by a government initiative to undertake common drug reviews, and the promotion of generic substitution have been the main levers used by public plans to improve the efficiency of drug expenditures.Private plans have historically covered all medicines authorised for sale in Canada, although this is changing in light of cost pressure.Overall, new drugs are available in the Canadian market on a timely basis, but maintaining comprehensive availability and accessibility may be an emerging challenge.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.919
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.120
GPT teacher head0.346
Teacher spread0.226 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it